Neoplasms

All Conditions

Rare Diseases

Liposarcoma

Neoplasms, Adipose Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Sarcoma

Soft Tissue Sarcoma

TQB3616 capsule (180mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.

TQB3616 placebo (0mg, quaque die, oral), 4 weeks (28 days) as a treatment cycle.

TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor

TQB3616 capsule

TQB3616 placebo

Yuhong Zhou, Doctor

Shikai Wu, Doctor

Wei Guo, Doctor

A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma

From randomization to the time of disease progression or death, whichever occurs first.

From randomization to the time of death from any cause.

For subjects whose best remission is complete remission or partial remission , it is defined as from the date when tumor remission is first recorded to the date when disease progression is first recorded or the date of death from any cause, whichever occurs first.

Percentage of complete or partial remission subjects as determined by RECIST 1.1.

Percentage of subjects with complete remission, partial remission, or disease stabilization at 6 weeks or more as determined by RECIST 1.1.

From the beginning of the crossover to the time of disease progression or death, whichever is first discovered

All adverse medical events that occurred after the subject received the investigational drug.

Spots Global Cancer Trial Database for tqb3616 placebo